PMID: 8584613Oct 1, 1995Paper

An open trial of the D1 antagonist SCH 39166 in six cases of acute psychotic states

Psychopharmacology
R de BeaurepaireT R Barnes

Abstract

Six psychotic patients were included in a four-week study of the effects of the D1 selective antagonist SCH 39166 given as monotherapy. Four had a diagnosis of schizophrenia, and two suffered from a schizoaffective disorder. All presented with an acute psychotic exacerbation at the beginning of the trial. SCH 39166 was progressively increased from 50 mg/day to 600 mg/day. In the four schizophrenic patients, the BPRS worsened, and three out of the four failed to complete the study because of this. Three schizophrenic patients were aggressive or violent after abrupt discontinuation of treatment. In the two patients with schizoaffective disorder the BPRS improved during the trial, but they had an acute relapse immediately after treatment discontinuation. Extrapyramidal symptoms improved in three of the six patients, and worsened in one.

References

Apr 29, 1992·European Journal of Pharmacology·R D McQuadeA Barnett
Jan 1, 1991·International Journal of Radiation Applications and Instrumentation. Part A, Applied Radiation and Isotopes·C HalldinG Sedvall
May 1, 1990·Trends in Pharmacological Sciences·R E Chipkin
Jan 1, 1989·Psychopharmacology Series·J HyttelM van den Berghe
Jan 1, 1980·Schizophrenia Bulletin·J M DavisC Chan
Feb 9, 1993·European Journal of Pharmacology·E P PrinssenA R Cools
Apr 1, 1993·Journal of Clinical Psychopharmacology·M A ParsaH Y Meltzer

❮ Previous
Next ❯

Citations

Oct 1, 1995·Psychopharmacology·T R Barnes, J Gerlach
Feb 24, 2006·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·Shitij KapurMing Li
Nov 14, 1997·Neuroscience and Biobehavioral Reviews·S A JosselynR J Beninger
Jul 31, 1998·Progress in Neuro-psychopharmacology & Biological Psychiatry·F I TaraziR J Baldessarini
Feb 19, 1998·Schizophrenia Research·J L WaddingtonE O'Callaghan
Jun 3, 2009·Schizophrenia Bulletin·Paul D Morrison, R M Murray
Oct 13, 2009·Clinical Pharmacokinetics·Shu-Feng Zhou
Nov 12, 2009·Clinical Pharmacokinetics·Shu-Feng Zhou
Nov 16, 2013·CNS Spectrums·Yong Kee ChoiFrank I Tarazi
Sep 4, 2008·Expert Opinion on Emerging Drugs·Ofer AgidGary Remington
Mar 8, 2016·Biological Psychiatry·Amy F T ArnstenRichard B Mailman
Jul 25, 2008·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Rodrigo D PazKuei Y Tseng
Dec 20, 2003·Annals of the New York Academy of Sciences·Marc LaruelleAnissa Abi-Dargham
Jan 12, 2005·European Psychiatry : the Journal of the Association of European Psychiatrists·Anissa Abi-Dargham, Marc Laruelle
Jun 24, 2015·British Journal of Pharmacology·Laura J MosherMarco Bortolato
Feb 15, 2014·Current Opinion in Pharmacology·Marc Laruelle
Oct 10, 2007·Harvard Review of Psychiatry·W Gordon Frankle
Nov 10, 2006·Journal of Psychopharmacology·Rudi HwangJames L Kennedy
Oct 29, 2003·The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry·Anissa Abi-Dargham, Holly Moore
Jun 24, 2018·Synapse·Yong Kee Choi, Frank I Tarazi
Apr 9, 2019·The International Journal of Neuropsychopharmacology·Per StenkronaLars Farde
Aug 30, 2014·Journal of Cognitive Neuroscience·Sven BestmannJoseph M Galea

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.